[Effect of hematologic treatment on the growth and puberty of children with thalassemia major].
This study reports on the endocrine abnormalities associated with delayed growth and puberty, observed in 10 children presenting with thalassemia major. Hormonal changes were followed up during treatment with regular transfusions and efficient chelating agents. Recovery of growth and onset of puberty were observed in most cases. When puberty was delayed, an associated substitutive treatment with sexual hormones was useful. In one case only, an isolated gonadotropic deficiency could be proven. In all cases STH, TSH and PRL secretions were normal. Without efficient and early treatment, the main consequence of the disease with respects to growth seems to be the risk of delayed puberty, mainly functional, or rarely hypogonadotropic due to definite LH and FSH deficiency.
D000293:Adolescent; D001803:Blood Transfusion; D001827:Body Height; D002648:Child; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000209:etiology / Q000628:therapy*; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D011628:Puberty, Delayed / Q000209:etiology / Q000628:therapy*; D013789:Thalassemia / Q000097:blood / Q000150:complications / Q000628:therapy*
D006728:Hormones; D005293:Ferritins; D003676:Deferoxamine
Effet du traitement hématologique sur la croissance et le développement pubertaire des enfants atteints de thalassémie majeure.